Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LVR013
MIFTS: 76

Liver Disease

Categories: Blood diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Disease

About this section

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 39 12 15 17
Liver Diseases 56 44 45 74
Liver Dysfunction 56 74
Liver Failure 56 74
Abnormality of the Liver 30
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 30
Hepatic Disease 15

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Liver diseases Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:409
ICD9CM 36 573.9
MeSH 45 D008107
NCIt 51 C3196
SNOMED-CT 69 62857009
Sources

Summaries for Liver Disease

About this section
MedlinePlus : 44 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and polycystic liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Metabolism and Selenium Micronutrient Network. The drugs Fentanyl and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 77 Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the... more...

Sources

Related Diseases for Liver Disease

About this section

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1155)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 34.7 ADIPOQ CYP2E1 INS PNPLA3 SLC17A5 TNF
2 polycystic liver disease 34.7 ALB GANAB PKHD1 PRKCSH
3 nonalcoholic fatty liver disease 34.7 ADIPOQ INS KRT18 PNPLA3
4 polycystic kidney disease 2 with or without polycystic liver disease 34.4 GANAB PKHD1 PRKCSH
5 fatty liver disease, nonalcoholic 1 34.4 ADIPOQ GPT INS KRT18 SLC17A5
6 alcoholic hepatitis 33.3 ALB CYP2E1 F2 GPT KRT18 SLC17A5
7 nonalcoholic steatohepatitis 33.0 ADIPOQ CYP2E1 F2 GPT INS KRT18
8 wilson disease 32.7 ALB F2 GPT
9 cholangitis, primary sclerosing 32.5 ABCB4 ALB DLAT GPT
10 sclerosing cholangitis 32.3 ABCB11 ABCB4 ALB TNF
11 acute liver failure 32.3 ALB F2 GPT SLC17A5
12 hepatic encephalopathy 32.3 ALB F2 GPT SLC17A5 TNF
13 cholestasis, progressive familial intrahepatic, 4 32.2 ABCB11 ABCB4
14 congenital hepatic fibrosis 32.1 PKHD1 SLC17A5
15 hepatitis 32.0 F2 GPT KRT18 SLC17A5 TNF
16 autoimmune hepatitis 31.9 DLAT F2 GPT
17 bile duct disease 31.8 ABCB11 ABCB4 ALB F2 GPT
18 cryptogenic cirrhosis 31.8 F2 KRT18
19 hepatitis b 31.6 ALB F2 GPT SLC17A5 TNF
20 alcoholic liver cirrhosis 31.6 ALB CYP2E1 F2 PNPLA3 SLC17A5
21 diabetes mellitus, noninsulin-dependent 31.5 ADIPOQ ALB GPT INS SLC17A5 TNF
22 hepatic coma 31.3 ALB F2 GPT
23 portal hypertension 31.3 ALB F2 GPT PKHD1 TNF
24 kidney disease 31.2 ADIPOQ ALB GANAB INS PKHD1
25 hepatitis a 31.1 ALB F2 GPT SERPINA1 TNF
26 viral hepatitis 31.0 ALB F2 GPT KRT18 SERPINA1 SLC17A5
27 sleep apnea 31.0 ADIPOQ INS TNF
28 alcohol abuse 31.0 CYP2E1 GPT SLC17A5
29 arteries, anomalies of 31.0 ADIPOQ ALB INS TNF
30 cholestasis 31.0 ABCB11 ABCB4 F2 GPT HSD3B7
31 body mass index quantitative trait locus 11 31.0 ADIPOQ CYP2E1 GPT INS PNPLA3 TNF
32 infantile liver failure syndrome 1 31.0 ALB F2 FAH GPT SLC17A5
33 hepatitis e 30.9 ALB F2 GPT TNF
34 atherosclerosis susceptibility 30.9 ADIPOQ INS TNF
35 peritonitis 30.8 ALB F2 TNF
36 cholangitis 30.8 ABCB11 ABCB4 ALB DLAT F2 GPT
37 cholelithiasis 30.7 ABCB4 ALB GPT
38 liver cirrhosis 30.7 ADIPOQ ALB CYP2E1 F2 GPT KRT18
39 dengue hemorrhagic fever 30.6 ALB F2 TNF
40 bilirubin metabolic disorder 30.6 ALB F2 GPT SLC17A5
41 scrub typhus 30.6 GPT SLC17A5 TNF
42 obstructive jaundice 30.5 ALB F2 GPT SLC17A5 TNF
43 schistosomiasis 30.5 ALB F2 TNF
44 endocarditis 30.4 ALB F2 TNF
45 hellp syndrome 30.3 F2 GPT SLC17A5
46 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.3 ADIPOQ INS
47 vascular disease 30.3 ADIPOQ ALB F2 INS TNF
48 apnea, obstructive sleep 30.2 ADIPOQ INS TNF
49 antipyrine metabolism 30.2 ALB F2
50 kwashiorkor 30.2 ALB F2 GPT SLC17A5

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease
Sources

Symptoms & Phenotypes for Liver Disease

About this section

UMLS symptoms related to Liver Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 F2
2 growth/size/body region MP:0005378 10.06 ABCB11 ABCB4 ADIPOQ F2 FAH HSD3B7
3 liver/biliary system MP:0005370 9.97 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 FAH
4 digestive/alimentary MP:0005381 9.91 ABCB4 ALB F2 HSD3B7 INS PKHD1
5 mortality/aging MP:0010768 9.77 ABCB11 ADIPOQ ALB CYP2E1 F2 FAH
6 neoplasm MP:0002006 9.1 ABCB4 ADIPOQ ALB CYP2E1 FAH TNF
Sources

Drugs & Therapeutics for Liver Disease

About this section

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
3
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
4
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1406-66-2 14986
5
Amlodipine Approved Phase 4,Phase 1 88150-42-9 2162
6
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
7
Telmisartan Approved, Investigational Phase 4,Phase 1 144701-48-4 65999
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198
9
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 7440-66-6 32051
10
Insulin glargine Approved Phase 4,Phase 2 160337-95-1
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
12
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
13
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
14
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
16 Orange Approved Phase 4,Phase 2,Not Applicable
17
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
18
Glucagon Approved Phase 4,Phase 2,Not Applicable 16941-32-5
19
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
20
Adefovir dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
21
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
22
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
23
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1405-86-3 3495
24
Alprostadil Approved, Investigational Phase 4,Phase 2,Phase 1 745-65-3 5280723 149351
25
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
26
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
27
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
28
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
29
Empagliflozin Approved Phase 4,Phase 2,Phase 1,Not Applicable 864070-44-0
30
Magnesium oxide Approved Phase 4 1309-48-4 14792
31
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
32
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
33
Insulin glulisine Approved Phase 4 207748-29-6
34
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
35
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
36
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
37
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
38
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1401-55-4
39
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147127-20-6 464205
40
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
41
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55981-09-4 41684
42
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
43
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 46783403 6436173
44
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 114-07-8 441411 12560
45
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79902-63-9 54454
46
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 215647-85-1, 99210-65-8
47
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 65666-07-1
48
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
49
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 525-66-6 4946
50
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147

Interventional clinical trials:

(show top 50) (show all 8774)
# Name Status NCT ID Phase Drugs
1 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Unknown status NCT02366845 Phase 4
2 Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
3 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
7 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
8 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
9 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
11 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
12 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
13 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
14 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
15 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
16 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
17 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
18 RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
19 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
20 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
21 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
22 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
23 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
24 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
25 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
26 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
27 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
28 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
29 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
30 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
31 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
32 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
33 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
34 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
35 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
36 Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02368288 Phase 4 entecavir
37 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
38 Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
39 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
40 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
41 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
42 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
43 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion Unknown status NCT02882113 Phase 4 Advagraf
44 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
45 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
46 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
47 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
48 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
49 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
50 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Disease:
Adult stem cell therapy for liver insufficiency
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Liver Disease:
Peripheral blood-derived hematopoietic stem cells PMIDs: 18181952 16556705 22121493
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver diseases

Sources

Genetic Tests for Liver Disease

About this section

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 30
2 Abnormality of the Liver 30
Sources

Anatomical Context for Liver Disease

About this section

MalaCards organs/tissues related to Liver Disease:

42
Liver, Testes, Kidney, T Cells, Bone, Lung, Heart
Sources

Publications for Liver Disease

About this section

Articles related to Liver Disease:

(show top 50) (show all 14250)
# Title Authors Year
1
Transplant-free Survival in Chronic Liver Disease Presenting as Acute Liver Failure in Childhood. ( 30028785 )
2019
2
How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis. ( 30227404 )
2019
3
Fatty liver disease is associated with the severity of acute pancreatitis:A systematic review and meta-analysis. ( 30986497 )
2019
4
Recurrent acute pancreatitis in a patient with both gallbladder and cystic duct agenesis and polycystic liver disease. ( 30792840 )
2019
5
Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. ( 30805370 )
2019
6
Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. ( 30727943 )
2019
7
Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. ( 30732129 )
2019
8
The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. ( 30791768 )
2019
9
A PDGFRβ-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. ( 31036530 )
2019
10
Liver disease in adults with severe alpha-1-antitrypsin deficiency. ( 30680526 )
2019
11
Alpha-1 Antitrypsin Deficiency Liver Disease, Mutational Homogeneity Modulated by Epigenetic Heterogeneity With Links to Obesity. ( 30681738 )
2019
12
Liver Disease due to Alpha-1 Antitrypsin Deficiency: Are we surprised that it is more complex than we thought? ( 31058323 )
2019
13
An exploratory phenome wide association study linking asthma and liver disease genetic variants to electronic health records from the Estonian Biobank. ( 30978214 )
2019
14
Comparison of variation in frequency for SNPs associated with asthma or liver disease between Estonia, HapMap populations and the 1000 genome project populations. ( 30659741 )
2019
15
Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature. ( 30984290 )
2019
16
Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. ( 30657626 )
2019
17
Autoimmune liver disease (primary biliary cholangitis/autoimmune hepatitis-overlap) associated with sarcoidosis (clinical cases and literature review). ( 31090378 )
2019
18
Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. ( 30872395 )
2019
19
Comparative analysis of bile acid spectrum in non-alcoholic fatty liver disease and cholelithiasis. ( 31094171 )
2019
20
Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms. ( 30693370 )
2019
21
Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis. ( 30063078 )
2019
22
Association between non-alcoholic fatty liver disease and colorectal cancer. ( 31092057 )
2019
23
Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. ( 30824851 )
2019
24
Liver disease is common in patients with common variable immunodeficiency and predicts mortality in the presence of cirrhosis or portal hypertension. ( 31026542 )
2019
25
Fetal-onset Congenital Dyserythropoietic Anemia Type 1 due to a Novel Mutation With Severe Iron Overload and Severe Cholestatic Liver Disease. ( 29668551 )
2019
26
Crohn's Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat Fraction Mapping. ( 30876963 )
2019
27
Pathophysiology of Cystic Fibrosis Liver Disease: a channelopathy leading to alterations in innate immunity and in microbiota. ( 31075352 )
2019
28
Cystic Fibrosis Associated Liver Disease in Lung Transplant Recipients. ( 31102574 )
2019
29
Unusual Cystic Fibrosis Transmembrane Conductance Regulator Mutations and Liver Disease: A Case Series and Review of the Literature. ( 30979466 )
2019
30
Case report: Cholecystoduodenostomy for cholestatic liver disease in a premature infant with cystic fibrosis and short gut syndrome. ( 30857526 )
2019
31
Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis. ( 30880274 )
2019
32
The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. ( 30947265 )
2019
33
SERPINA1 Z allele is associated with cystic fibrosis liver disease. ( 30739910 )
2019
34
Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease. ( 30600723 )
2019
35
A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. ( 30697907 )
2019
36
The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. ( 30054796 )
2019
37
Association between Sarcopenia and Depression in Patients with Chronic Liver Diseases. ( 31072067 )
2019
38
A Behavioral Health Program for Alcohol Use Disorder, Substance Abuse, and Depression in Chronic Liver Disease. ( 31061953 )
2019
39
Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link? ( 31089474 )
2019
40
Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. ( 30993553 )
2019
41
Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. ( 30961499 )
2019
42
Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. ( 30970431 )
2019
43
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. ( 30788048 )
2019
44
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. ( 30734333 )
2019
45
Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. ( 30745809 )
2019
46
Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. ( 30765935 )
2019
47
Fatal case of necrotising fasciitis due to Vibrio vulnificus in a patient with alcoholic liver disease and diabetes mellitus. ( 30659010 )
2019
48
Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. ( 30428692 )
2019
49
Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. ( 30470912 )
2019
50
Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. ( 30089409 )
2019
Sources

Variations for Liver Disease

About this section
Sources

Expression for Liver Disease

About this section
Search GEO for disease gene expression data for Liver Disease.
Sources

Pathways for Liver Disease

About this section

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Metabolism 67
Show member pathways
 13.68 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 DLAT
2
Selenium Micronutrient Network 1
Show member pathways
 11.96 ALB F2 INS TNF
3
Type II diabetes mellitus 1 38
Show member pathways
 11.53 ADIPOQ INS TNF
4
Adipogenesis 1
11.38 ADIPOQ INS PNPLA3 TNF
5
FOXA2 and FOXA3 transcription factor networks 1
10.98 ALB F2 INS
6
Farnesoid X Receptor Pathway 1
10.71 ABCB11 ABCB4
7
Cori Cycle 1
10.61 GPT INS
8
Nuclear Receptors in Lipid Metabolism and Toxicity 1
10.34 ABCB11 ABCB4 CYP2E1
Sources

GO Terms for Liver Disease

About this section

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.87 ADIPOQ ALB CYP2E1 GANAB HSD3B7 PRKCSH
2 extracellular exosome GO:0070062 9.85 ABCB11 ABCB4 ALB F2 FAH GANAB
3 intercellular canaliculus GO:0046581 9.26 ABCB11 ABCB4
4 endoplasmic reticulum lumen GO:0005788 9.1 ALB F2 GANAB INS PRKCSH SERPINA1
5 glucosidase II complex GO:0017177 8.96 GANAB PRKCSH

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to bacterium GO:0009617 9.65 ADIPOQ CYP2E1 SLC17A5
2 negative regulation of lipid catabolic process GO:0050995 9.46 INS TNF
3 positive regulation of cellular protein metabolic process GO:0032270 9.43 ADIPOQ INS
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 F2 INS TNF
5 negative regulation of gluconeogenesis GO:0045721 9.4 ADIPOQ INS
6 N-glycan processing GO:0006491 9.37 GANAB PRKCSH
7 cellular protein metabolic process GO:0044267 9.35 ALB F2 INS PRKCSH SERPINA1
8 acute-phase response GO:0006953 9.33 F2 INS SERPINA1
9 regulation of protein secretion GO:0050708 9.32 INS TNF
10 glucose metabolic process GO:0006006 8.92 ADIPOQ DLAT INS TNF

Molecular functions related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.8 INS SERPINA1 TNF
Sources

Sources for Liver Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....